Conolidine’s analgesic effects stem from its interaction with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors from the central nervous method, conolidine modulates alternate molecular targets. A Science Improvements review observed that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regu